<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02560623</url>
  </required_header>
  <id_info>
    <org_study_id>15-004540</org_study_id>
    <nct_id>NCT02560623</nct_id>
  </id_info>
  <brief_title>Minimally-Invasive Detection of Barrett's Esophagus and Barrett's Esophagus Related Dysplasia/Carcinoma</brief_title>
  <official_title>Minimally-Invasive Detection of Barrett's Esophagus and Barrett's Esophagus Related Dysplasia/Carcinoma by a Sponge on String Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Exact Sciences Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate if the capsule sponge device can detect the presence of Barrett's&#xD;
      Esophagus&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assess the sensitivity and specificity of a panel of DNA methylation markers in the&#xD;
      non-endoscopic detection of Barrett's Esophagus as well as dysplasia/carcinoma using a&#xD;
      capsule sponge device.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and specificity of Barrett's Esophagus Diagnosis</measure>
    <time_frame>2 years. Interim analysis after 50% recruitment is complete at approximately 9 months.</time_frame>
    <description>The sensitivity and specificity of methylated DNA markers detected by the capsule sponge, in making a diagnosis of BE will be assessed using endoscopic examination as a gold standard.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and specificity of Barrett's dysplasia detection</measure>
    <time_frame>2 years. Interim analysis after 50% recruitment is complete at approximately 9 months.</time_frame>
    <description>The sensitivity and specificity of methylated DNA markers detected by the capsule sponge, in making a diagnosis of BE related dysplasia will be assessed using endoscopic surveillance biopsy histology as a gold standard.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Barrett's Esophagus</condition>
  <arm_group>
    <arm_group_label>Cases - Barrett's Esophagus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will have sponge capsule procedure, blood draw, and clinically indicated endoscopy with endoscopic brushings of the esophagus.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls - No Barrett's Esophagus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will have sponge capsule procedure, blood draw, and clinically indicated endoscopy with endoscopic biopsies of the esophagus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sponge capsule</intervention_name>
    <description>Subjects will swallow sponge capsule and esophageal cells will be collected on deployed sponge.</description>
    <arm_group_label>Cases - Barrett's Esophagus</arm_group_label>
    <arm_group_label>Controls - No Barrett's Esophagus</arm_group_label>
    <other_name>EsophaCap</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        Subjects with known Barrett's Esophagus (BE).&#xD;
&#xD;
          1. Patient between the ages 18 - 90.&#xD;
&#xD;
          2. Patients with a BE segment â‰¥ 1cm in maximal extent endoscopically.&#xD;
&#xD;
          3. Histology showing evidence of intestinal metaplasia with or without presence of&#xD;
             dysplasia.&#xD;
&#xD;
          4. Undergoing clinically indicated endoscopy.&#xD;
&#xD;
        Subjects without known evidence of BE&#xD;
&#xD;
        1. Undergoing clinically indicated diagnostic endoscopy.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Subjects with known BE.&#xD;
&#xD;
          1. Patients with prior history of ablation (photodynamic therapy, radiofrequency&#xD;
             ablation, cryotherapy, argon plasma coagulation). Patients with history of endoscopic&#xD;
             mucosal resection alone will not be excluded.&#xD;
&#xD;
          2. Patients with history of esophageal resection for esophageal carcinoma.&#xD;
&#xD;
        Subjects with or without known evidence of BE (on history or review of medical records).&#xD;
&#xD;
          1. Pregnant or lactating females.&#xD;
&#xD;
          2. Patients who are unable to consent.&#xD;
&#xD;
          3. Patients with current history of eosinophilic esophagitis, achalasia or uninvestigated&#xD;
             dysphagia.&#xD;
&#xD;
          4. Patients on oral anticoagulation including Coumadin, Warfarin.&#xD;
&#xD;
          5. Patients on antiplatelet agents including Clopidogrel, unless discontinued for 3 days&#xD;
             prior to the sponge procedure.&#xD;
&#xD;
          6. Patients on oral thrombin inhibitors including Dabigatran and oral factor X a&#xD;
             inhibitors such as rivaroxaban, apixaban and edoxaban, unless discontinued for 3 days&#xD;
             prior to the sponge procedure.&#xD;
&#xD;
          7. Patients with history of known varices or cirrhosis.&#xD;
&#xD;
          8. Patients with history of esophageal resection for esophageal carcinoma.&#xD;
&#xD;
          9. Patients with congenital or acquired bleeding diatheses.&#xD;
&#xD;
         10. Patients with a history of esophageal squamous dysplasia.&#xD;
&#xD;
         11. Patient has known carcinoma of the foregut (pancreatic, bile duct, ampullary, stomach,&#xD;
             or duodenum) within 5 years prior to study enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prasad G Iyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Health Systems - Austin</name>
      <address>
        <city>Austin</city>
        <state>Minnesota</state>
        <zip>55912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Health System - Mankato</name>
      <address>
        <city>Mankato</city>
        <state>Minnesota</state>
        <zip>56001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 21, 2015</study_first_submitted>
  <study_first_submitted_qc>September 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2015</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Prasad G. Iyer</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Barrett's</keyword>
  <keyword>esophagus</keyword>
  <keyword>reflux</keyword>
  <keyword>esophageal adenocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Barrett Esophagus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

